Key Details
Price
$0.63Annual ROE
-82.11%Beta
0.89Events Calendar
Next earnings date:
Mar 27, 2025Recent quarterly earnings:
Nov 13, 2024Recent annual earnings:
Mar 27, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Sep 3, 2024Analyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
BEDMINSTER, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of Evelyn D'An to its Board of Directors as an independent director and Chair of the Audit Committee, effective Wednesday, February 5, 2025.
BEDMINSTER, N.J. , Jan. 10, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces that on January 6, 2025, it received a NYSE American LLC notice indicating that the Company has fallen below certain NYSE American continued listing standards because it failed to hold its annual meeting of stockholders for the fiscal year ending on December 31, 2024, as set forth in Section 704 of the NYSE American Company Guide.
Signs non-binding term sheet granting global rights to develop and commercialize oral MAT2203 for invasive aspergillosis and potentially other invasive fungal infections
Matinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Call Transcript
Matinas BioPharma Holdings, Inc. (NYSE:MTNB ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Jody Cain - LHA IR Jerry Jabbour - CEO Terri Matkovits - CDO Terry Ferguson - CMO Keith Kucinski - CFO Conference Call Participants Julian Harrison - BTIG Operator Welcome to the Matinas BioPharma Third Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
Let's talk penny stocks, those under-five-dollar shares that buzz with potential. They're nimble, sensitive to the slightest news, and can pivot on a dime.
BEDMINSTER, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small molecules and small oligonucleotides with its lipid nanocrystal (LNC) platform technology, announces that Jerome D. Jabbour, Chief Executive Officer, will present a company overview and hold meetings with institutional investors at two upcoming investment conferences:
Matinas Biopharma Holdings, Inc. (MTNB) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago.
BEDMINSTER, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announces that it will report first quarter 2023 financial results after market close on Wednesday, May 10, 2023. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
FAQ
- What is the ticker symbol for Matinas BioPharma Holdings?
- Does Matinas BioPharma Holdings pay dividends?
- What sector is Matinas BioPharma Holdings in?
- What industry is Matinas BioPharma Holdings in?
- What country is Matinas BioPharma Holdings based in?
- When did Matinas BioPharma Holdings go public?
- Is Matinas BioPharma Holdings in the S&P 500?
- Is Matinas BioPharma Holdings in the NASDAQ 100?
- Is Matinas BioPharma Holdings in the Dow Jones?
- When was Matinas BioPharma Holdings's last earnings report?
- When does Matinas BioPharma Holdings report earnings?
- Should I buy Matinas BioPharma Holdings stock now?